Effect of DL-3-n-Butylphthalide on Cerebral Hypoperfusion Due to Atherosclerotic Stenosis: A Multicenter, Double-Blind, Randomized Controlled, Preliminary Trial

作者：Dawei Chen, Xinxin Chang, Bei Pan, Yumeng Li, Feng Qiu, Yonghong Tang, Xiaoping Gao, Yanwei Yin, Fen Yang, Yu Wang, Jiang Zhang, M Wang, Zhengyu Zhu, Yanping Guo, Degang Sun, Wensheng Tian, Hui Yu, Yafen Wei, Yadong Yu, Yi Zhao, Manli Sun, 侯有文, Hui Li, Saizhen Wu, Xiangsheng Li, Xiaoxuan Ma, Feng Huang, Xiaoyan Yan, Jian Wu, Fei Wang, Keyun Liu, Jinsheng Lin, Changlin Wang, Zhu HaiSheng, Xiaofan Pan, Jun Chang, Bo Zhang, Xiangyang Zhu, Bixia Huang, Xiufang Dong, Hongbo Dai, Jianbo He, Qiang Ma, Wuzhou Wang, Qingsong Yang, Li Cao, Bingcang Yan, Jin Shi · 发表于：CNS Drugs · 年份：2026 · DOI：10.1007/s40263-026-01293-w · 研究领域：Neurological Disease Mechanisms and Treatments、Cerebrovascular and Carotid Artery Diseases、Traditional Chinese Medicine Analysis

BACKGROUND: Augmentation of collateral circulation is an alternative method to improve cerebral hypoperfusion when revascularization is not suitable. DL-3-n-butylphthalide (NBP) has been shown to enhance cerebral collateral circulation and improve cerebral blood flow (CBF) in previous studies. The objective of this study was to explore the effect of NBP on cerebral hemodynamic impairment due to atherosclerotic stenosis in internal carotid system. METHODS: This was a double-blind, placebo-controlled, randomized clinical trial conducted in 38 Chinese hospitals between 14 January 2022, and 11 April 2024. Eligible participants were aged 35-85 years with ≥ 70% stenosis in unilateral internal carotid artery or middle cerebral artery, accompanied by cerebral hypoperfusion and no recent cerebral ischemic events. The patients were randomly assigned in a 1:1 ratio to a treatment group receiving 600 mg NBP daily or a placebo group receiving an ineffective dose of NBP daily for 4 weeks. The cerebral perfusion was assessed by computed tomography perfusion. The grades of cerebral perfusion change from baseline to 12 weeks were classified into amelioration, stabilization, and deterioration. The primary efficacy outcome was the percentage of patients achieving CBF amelioration. RESULTS: Of 485 enrolled patients (median age 63 years, 66.6% men), 244 were assigned to the NBP group and 241 to the placebo group. At the end of follow-up, 204 in the NBP group and 212 in the placebo group completed...